Cargando…
Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada
For patients with Mantle Cell Lymphoma (MCL), there is no recognized standard of care for relapsed/refractory (R/R) disease after treatment with a Bruton’s tyrosine kinase inhibitor (BTKi). Brexucabtagene autoleucel (brexu-cel) represents a promising new treatment modality in MCL. We explored whethe...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946986/ https://www.ncbi.nlm.nih.gov/pubmed/35323364 http://dx.doi.org/10.3390/curroncol29030164 |
_version_ | 1784674331156021248 |
---|---|
author | Ball, Graeme Lemieux, Christopher Cameron, David Seftel, Matthew D. |
author_facet | Ball, Graeme Lemieux, Christopher Cameron, David Seftel, Matthew D. |
author_sort | Ball, Graeme |
collection | PubMed |
description | For patients with Mantle Cell Lymphoma (MCL), there is no recognized standard of care for relapsed/refractory (R/R) disease after treatment with a Bruton’s tyrosine kinase inhibitor (BTKi). Brexucabtagene autoleucel (brexu-cel) represents a promising new treatment modality in MCL. We explored whether brexu-cel was cost-effective for the treatment of R/R MCL. We developed a partitioned survival mixture cure approach to model the costs and outcomes over a lifetime horizon. The clinical data were derived from the ZUMA-2 clinical trial. The costs were estimated from the publicly available Canadian databases, published oncology literature, and pan-Canadian Oncology Drug Review economic guidance reports. The health state utilities were sourced from the ibrutinib submission to the National Institute for Health and Care Excellence for R/R MCL and supplemented with values from the published oncology literature. In the base case over a lifetime horizon, brexu-cel generated an incremental 9.56 life-years and an additional 7.03 quality-adjusted life-years compared to BSC, while associated with CAD 621,933 in additional costs. The resultant incremental cost-utility ratio was CAD 88,503 per QALY gained compared with BSC. Based on this analysis, we found brexu-cel to be a cost-effective use of healthcare resources relative to BSC for treatment of adult patients with R/R MCL previously treated with a BTKi in Canada, though additional research is needed to confirm these results using longer follow-up data. |
format | Online Article Text |
id | pubmed-8946986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89469862022-03-25 Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada Ball, Graeme Lemieux, Christopher Cameron, David Seftel, Matthew D. Curr Oncol Article For patients with Mantle Cell Lymphoma (MCL), there is no recognized standard of care for relapsed/refractory (R/R) disease after treatment with a Bruton’s tyrosine kinase inhibitor (BTKi). Brexucabtagene autoleucel (brexu-cel) represents a promising new treatment modality in MCL. We explored whether brexu-cel was cost-effective for the treatment of R/R MCL. We developed a partitioned survival mixture cure approach to model the costs and outcomes over a lifetime horizon. The clinical data were derived from the ZUMA-2 clinical trial. The costs were estimated from the publicly available Canadian databases, published oncology literature, and pan-Canadian Oncology Drug Review economic guidance reports. The health state utilities were sourced from the ibrutinib submission to the National Institute for Health and Care Excellence for R/R MCL and supplemented with values from the published oncology literature. In the base case over a lifetime horizon, brexu-cel generated an incremental 9.56 life-years and an additional 7.03 quality-adjusted life-years compared to BSC, while associated with CAD 621,933 in additional costs. The resultant incremental cost-utility ratio was CAD 88,503 per QALY gained compared with BSC. Based on this analysis, we found brexu-cel to be a cost-effective use of healthcare resources relative to BSC for treatment of adult patients with R/R MCL previously treated with a BTKi in Canada, though additional research is needed to confirm these results using longer follow-up data. MDPI 2022-03-17 /pmc/articles/PMC8946986/ /pubmed/35323364 http://dx.doi.org/10.3390/curroncol29030164 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ball, Graeme Lemieux, Christopher Cameron, David Seftel, Matthew D. Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada |
title | Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada |
title_full | Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada |
title_fullStr | Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada |
title_full_unstemmed | Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada |
title_short | Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada |
title_sort | cost-effectiveness of brexucabtagene autoleucel versus best supportive care for the treatment of relapsed/refractory mantle cell lymphoma following treatment with a bruton’s tyrosine kinase inhibitor in canada |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946986/ https://www.ncbi.nlm.nih.gov/pubmed/35323364 http://dx.doi.org/10.3390/curroncol29030164 |
work_keys_str_mv | AT ballgraeme costeffectivenessofbrexucabtageneautoleucelversusbestsupportivecareforthetreatmentofrelapsedrefractorymantlecelllymphomafollowingtreatmentwithabrutonstyrosinekinaseinhibitorincanada AT lemieuxchristopher costeffectivenessofbrexucabtageneautoleucelversusbestsupportivecareforthetreatmentofrelapsedrefractorymantlecelllymphomafollowingtreatmentwithabrutonstyrosinekinaseinhibitorincanada AT camerondavid costeffectivenessofbrexucabtageneautoleucelversusbestsupportivecareforthetreatmentofrelapsedrefractorymantlecelllymphomafollowingtreatmentwithabrutonstyrosinekinaseinhibitorincanada AT seftelmatthewd costeffectivenessofbrexucabtageneautoleucelversusbestsupportivecareforthetreatmentofrelapsedrefractorymantlecelllymphomafollowingtreatmentwithabrutonstyrosinekinaseinhibitorincanada |